Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 8224 results

  1. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  2. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. Accuro handheld ultrasound device for locating intervertebral space for administration of spinal anaesthesia

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development Reference number: GID-TA10700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development Reference number: GID-TA11018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  13. Third molars (impacted) - prophylactic removal [ID898]

    In development Reference number: GID-TAG525 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development Reference number: GID-TA11338 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development